The rationale for combining CSF1R blockade with CD40a as a strategy to overcome resistance to checkpoint inhibition was motivated by preclinical studies in which this combination fostered a proinflammatory tumor milieu, T-cell stimulation, and TAM depletion [8, 9]. The gene discussed is CSF1R; the disease is neoplasm.